The Patent Cliff Isn’t a Crisis — It’s a Call to Action for Equipment Suppliers
In the pharmaceutical industry, few events are as anticipated—and as feared—as the patent cliff. When blockbuster drugs lose patent protection, the resulting revenue drop c…
Unlocking the Future of Biopharma Contracts: How Patent Data Can Be Your Secret Weapon
In the fiercely competitive world of biopharmaceuticals, success isn’t just about groundbreaking science or innovative therapies — it’s also about strategic timing a…
ð¨ The Hidden Power of Patent Expiry Data: How Pharma Giants and Innovators Can Stay Ahead Without Hiring Extra Analysts ð¨
In the fiercely competitive world of pharmaceuticals, timing is everything. The expiration of a drug patent isn’t just a dat…
Track Global Drug Patent Expiry by Geography — Without Hiring a Team of Analysts Read Post »
Is Your Oncology Sales Pipeline at Risk? How to Capitalize on the Patent Cliff Before It’s Too Late
In the fast-paced world of oncology, innovation is both a blessing and a curse. While groundbreaking therapies promise hope for patients, they also hera…
The Patent Cliff Is Approaching—Are You Ready to Seize the Biosimilar First-Mover Advantage?
In the rapidly evolving landscape of biopharmaceuticals, the looming patent cliff is no longer a distant threat—it’s a pressing reality that could redefine mar…
The $200 Billion Battle Over Bioequivalence: Why It Matters More Than Ever for Patients and the Industry
Imagine a world where billions of dollars are spent on a seemingly simple question: Are generic drugs truly the same as their brand-name counterpar…
Prove It’s the Same: The $200 Billion Bioequivalence Fight Reshaping Generic Drugs Read Post »
In the relentless race to bring groundbreaking medicines to market, the path from lab to patient is fraught with hurdles—regulatory, financial, and scientific. Yet, amid these challenges, a strategic pathway emerges that could redefine how pharmaceutic…
In the relentless world of pharmaceutical innovation, the recent enactment of the Inflation Reduction Act (IRA) has sent shockwaves through the industry—yet many stakeholders remain uncertain about what it truly entails and how it will reshape drug pri…
The IRA Price Reset: What It Actually Does to Pharma Pricing, and What Comes Next Read Post »
In the relentless race to innovate, pharmaceutical companies have long relied on a strategic playbook: "evergreening." This tactic involves making minor modifications to existing drugs—new formulations, delivery methods, or slight chemical tw…
When the Patent Wall Crumbles: Secondary Abandonment and the Death of Drug Evergreening Read Post »
In the high-stakes world of pharmaceuticals, innovation alone isn’t enough. The real game-changer lies in strategic patent licensing—unlocking hidden value, accelerating drug development, and gaining a competitive edge. Yet, many companies stumble when…
The Strategic Playbook for Identifying and Securing Drug Patent Licensing Opportunities Read Post »
Get new actionable insights and updates from BiotechBlog
